MedTrace Logo

Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH

NCT00818870 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-01-27

No results posted yet for this study

Summary

The study is designed to assess and compare the effect of Vecam 40/300, Vecam 20/300 and Omeprazole 20 mg (a standard FDA approved GERD treatment) on the control of gastric pH.

Conditions

  • Gastroesophageal Reflux

Interventions

DRUG

Omeprazole

20 mg capsule, orally, once daily (before breakfast) for 5 days.

DRUG

Vecam

1 capsule, orally, once daily at bedtime for 5 days.

DRUG

Vecam

1 capsule, orally, once daily at bedtime for 5 days.

Sponsors & Collaborators

  • Vecta Ltd.

    lead INDUSTRY

Principal Investigators

  • Vijayalakshmi S Pratha, MD · Clinical Applications Laboratories Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00818870 on ClinicalTrials.gov